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-Cells are the core effector of glycemic control, and
when largely lost in the course of type 1 diabetes,
glycemic control is no longer guaranteed. Although
glycemic control can be established by insulin
injections, diabetic patients still suffer from microvascular
(nephropathy, retinopathy, neuropathy) and macrovascular
(ischemic heart disease, cerebrovascular disease, periph-
eral vascular disease) complications, resulting in a lower
life expectancy (1). Therefore, islet transplantation has
been implemented as one therapeutic means to achieve
a more physiologic form of glycemic control. Although high
rates of insulin independence can be achieved shortly after
transplantation, the rate of insulin independence after
longer time intervals remains suboptimal, especially in view
of the potential complications of immunosuppressive
treatment (2). One of the reasons for the limited clinical
success of islet transplantation is the exposure of the islets
to stress prior to and in the ﬁrst weeks after trans-
plantation. The liver may actually not be an optimal trans-
plantation site (although it connects the islets to the blood
ﬂow from the portal vein). Also, it has been shown that
islet grafts will only be fully vascularized after 1–2 weeks,
reaching the ﬁnal state of vascularization even later (3). As
a consequence of the lack of nutrients and hypoxia, to-
gether with other factors such as hyperglycemia and im-
munosuppressant toxicity, to name only two of them,
a considerable proportion of the transplanted b-cells will
undergo apoptosis, further limiting the success of islet
transplantation.
In order to optimize the treatment of patients after islet
transplantation, a methodology has been sought that
would allow for in vivo transplanted islets to be followed
noninvasively. The ﬁrst method that allowed for imaging of
transplanted islets in vivo was described in 2004 by Jirák
et al. (4). They demonstrated that b-cells could be labeled
with superparamagnetic iron oxide particles (SPIOs) and
detected by MRI in vivo in a rodent model. It was shown
later that islets prelabeled with SPIOs could be followed
for 6 months after transplantation (5) and that the signal
was speciﬁc for islets. Although false-positive results due
to macrophaged SPIOs outside of the transplanted islets
remain a concern, the authors did not ﬁnd evidence for
this. Another major concern associated with this technol-
ogy has always been the potential damage to the b-cells by
the transfection procedure and the toxicity of the SPIOs
themselves. Although it has been demonstrated that b-cells
can be labeled with SPIOs without functional impairment,
it seems to remain a challenge to load the b-cells with the
right amount of SPIOs to guarantee in vivo detectability by
MRI and at the same time avoid toxic effects. It appears
that the labeling protocols need to be followed thoroughly
(6). Therefore, alternative methods have been established
for visualization of transplanted b-cells. Although techni-
ques that would use genetically modiﬁed b-cells for trans-
plantation are at this point in time not suitable for imaging
in humans (7,8) (and also have been dependent on the in-
sulin promoter giving limited extra information on top of
insulin production), speciﬁc radiolabeled tracer molecules
c a nb eu s e df o ri m a g i n go ft r a n s p l a n t e di s l e t sb yP E T
(positron emission tomography) or SPECT (single photon
emission computed tomography). It has been demonstrated
that islet grafts can be visualized in vivo by targeting VMAT2
(vasoactive monoamine transporter 2) or the GLP-1 re-
ceptor (glucagon-like peptide-1) (9–11). These approaches
have the advantage that they can be used at any time point
by injecting the tracer molecule and do not require prel-
abeling of the b-cells prior to transplantation. So, why
should one continue to monitor islet transplants in vivo by
MRI using the rather complicated prelabeling strategy?
A number of therapeutic strategies have been used to
increase the survival of freshly transplanted b-cells.
Transfection of b-cells with siRNA (small interfering RNA)
silencing caspase-3 has been shown to result in inhibition
of apoptosis, but the effect was limited to a few days; an
adenoviral vector was therefore used to guarantee stable
expression of the silencing RNA (12). However, trans-
fecting b-cells by means of an adenovirus may also cause
apoptosis (13) and is a problem when it comes to clinical
b-cell transplantation in humans. So, other therapeutic
approaches seem to be necessary, although gene sup-
pression by means of silencing RNA appears to be a very
elegant, attractive method.
The group of Anna Moore (5,6,14) is taking the ﬁeld of
b-cell imaging a great stride forward (Fig. 1). Although not
avoiding the challenging prelabeling strategy for MR im-
aging of transplanted islets, the group effectively takes
advantage of the therapeutic potential of nanoparticles
used as a contrast agent. By conjugating the nanoparticles
to the siRNA targeting human caspase-3, the silencing RNA
remains inside the cell without the necessity of genetically
modifying the b-cells. By this elegant approach, a pro-
longed effect of the siRNA can be obtained, and as shown
by MR imaging, the volume of the siRNA-treated graft was
signiﬁcantly larger than the untreated control graft, while
the rate of apoptosis was lower. Although the long-term
effects on islet survival and glycemic control remain to be
elucidated, the proof of principal for the use of this com-
bined diagnostic and therapeutic approach has been
demonstrated. Although delivery of therapeutic nano-
particles labeled with SPIOs for tumor targeting in vivo has
previously been described (14), we must keep in mind that
imaging of b-cells is much more of a challenge than im-
aging of tumors. Tumors are focally growing, metabolically
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COMMENTARYhyperactive cell clusters that overexpress many receptors
and transport proteins as potential targets for imaging,
rendering targeting much less of a challenge than in the
case of b-cells/islets. The results of this article are in line
with those of another recently published study showing
that the use of ﬂuorinated alginate microcapsules in-
creased the insulin secretion rate of human islets and at
the same time provided a signal for detection by MRI and
contrast for ultrasound and CT imaging (15). It therefore
appears that the ﬁrst steps toward therapeutic molecular
imaging of islets have been taken.
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FIG. 1. This ﬁgure shows the main approaches to imaging of b-cells at this point in time. SPIOs have been used for labeling of islets prior to
transplantation since 2004 (left). Other MRI contrast agents are currently under investigation and potentially also allow for quantiﬁcation by MRI
spectroscopy. For the determination of the pancreatic b-cell mass, PET and SPECT imaging with highly speciﬁc radiotracers seem to be the
techniques of choice today (middle). MRI imaging of native islets using the calcium analog Mg
++ as contrast agent has successfully been performed
for imaging of the functional pancreatic b-cells. The approach using siRNA-coated nanoparticles, providing contrast for diagnostics (MRI) and at
the same time exerting therapeutic effects that increase the islet survival, is taking b-cell imaging to a new level (right). (A high-quality digital
representation of this ﬁgure is available in the online issue.)
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